Please assess the completion status of the following clinical trial:

Trial Title: Effect of LIK066 on Body Weight in Patients With Elevated Body Mass Index

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Key Inclusion Criteria:~* Subjects with stable health condition as determined by past medical history, physical examination, electrocardiogram, and laboratory tests at screening.~* Patients with dysglycemia are patients with: Fasting plasma glucose \>100mg/dL (5.6 mmol/L), or HbA1c \> 5.7% and \< 10% at screening.~* Fasting plasma glucose ≤250mg/dL (13.9 mmol/L) at screening.~* If treated with antidiabetic medications (other than prohibited medications), patients must be on a stable dose for 12 weeks prior to randomization and maintain the dose until the end of the study.~* Subjects must have a body mass index (BMI) within the range of 35 - 50 kg/m2 at screening, with stable body weight (± 5 kg) within 3 months prior to screening~Key Exclusion Criteria:~* Pre-existing, clinically significant gastrointestinal, liver, cardiovascular, renal or other chronic medical condition which is considered serious or unstable, other than stable cardiovascular disease, treated hypertension, dyslipidemia or other stable chronic disorders~* Clinically significant GI disorder related to malabsorption or that may affect drug or glucose absorption or history of significant gastrointestinal surgery that could affect intestinal glucose absorption~* Enrollment in a diet, weight loss or exercise programs with the specific intent of losing weight, within 3 months prior to randomization, or clinical diagnosis of any eating disorder~* Pregnant or nursing (lactating) women, and women of child-bearing potential

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Part 1: LIK066 150 mg once daily (qd) (Type: EXPERIMENTAL): LIK066 150 mg qd within 15 minutes before starting lunch
- Part 1: Placebo once daily (Type: PLACEBO_COMPARATOR): Matching placebo tablets of LCZ696 150 mg within 15 minutes before starting lunch.
- Part 2: LIK066 75 mg twice daily (bid) (Type: EXPERIMENTAL): LIK066 75 mg bid before breakfast and dinner
- Part 2: LIK066 50 mg three times daily (tid) (Type: EXPERIMENTAL): LIK066 50 mg tid before all 3 meals;
- Part 2: Placebo three times daily (Type: PLACEBO_COMPARATOR): Matching placebo tablets tid before meals.

Based on this trial design, predict the completion outcome and termination type (if applicable).